Speaker
Adam Miller
Speaker's Institution
Colorado State University
Date
2025-11-04
Time
4:00pm
Location
Chemistry A101
Mixer Time
3:45pm
Mixer Time
Chemistry B101E
Calendar (ICS) Event
Additional Information
About the seminar:
[64/67Cu]Cu-SAR-bisPSMA is a radiotheranostic agent which received a fast-track designation by the FDA earlier this year and is currently in clinical trials. Copper radioisotopes are underutilized in radiopharmaceuticals due to thermodynamic and kinetic instability of Cu2+ ions in vivo with many of the common chelators used in radiopharmaceuticals such as cyclam, DOTA, and TETA. Sarcophagine (SAR) is a macrocyclic chelator that provides excellent stability with Cu2+ and allows for bivalent functionalization with targeting peptides for proteins such as Prostate-Specific Membrane Antigen (PSMA), which is overexpressed on prostate cancer tumors. [64/67Cu]Cu-SAR-bisPSMA is a significant development in radiopharmaceuticals due to the stability of SAR with Cu2+ radioisotopes, 64Cu’s longer half-life than other radioisotopes used with PSMA agents, bivalent functionalization of the chelator which enhances binding of the agent, and the ability to design a theranostic combo for one type of ion. This seminar will examine the historical development of Sarcophagine as a chelator and its application to Cu-based radiopharmaceuticals.
